this stock is not 4 the faint hearted but , page-6

Umm I am not sure they are going too lose another $15 million in the second half of this fy.
They increased there number of devices in the previous half too get ahead of demand so hopefully they will in the 2nd half be implanting more devices than they are making which would bring cost right down.
Also they stated that the beaurocracy in gaining trial approval is also expensive and that too has been dealt with reducing costs.
Only time will tell but definately feel the tide maybe turning.